Stockscreener 앱 받기
10.96
3.89%
0.41
시간 외 거래:
10.96
전일 마감가:
$10.55
열려 있는:
$10.78
하루 거래량:
94,279
Relative Volume:
0.74
시가총액:
$201.62M
수익:
-
순이익/손실:
$-39.57M
주가수익비율:
-4.2801
EPS:
-2.5607
순현금흐름:
$-36.97M
1주 성능:
-6.16%
1개월 성능:
-0.18%
6개월 성능:
+1.01%
1년 성능:
+31.89%
1일 변동 폭
$10.29
$11.30
1주일 범위
$10.28
$12.06
52주 변동 폭
$4.60
$14.93
Elicio Therapeutics Inc Stock (ELTX) Company Profile
명칭
Elicio Therapeutics Inc
전화
(857) 209-0050
주소
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
10.96 | 194.08M | 0 | -39.57M | -36.97M | -2.5607 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Elicio Therapeutics Inc Stock (ELTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Rodman & Renshaw | Buy |
Elicio Therapeutics Inc 주식(ELTX)의 최신 뉴스
Behavioral Patterns of ELTX and Institutional Flows - Stock Traders Daily
Earnings Report: Does Elicio Therapeutics Inc offer margin of safetyQuarterly Risk Review & Weekly High Return Forecasts - baoquankhu1.vn
If You Invested $1,000 in Elicio Therapeutics, Inc. (ELTX) - Stock Titan
How do insiders feel about Elicio Therapeutics IncWeekly Trend Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Aug Macro: How do insiders feel about Elicio Therapeutics IncWeekly Trend Recap & Daily Profit Focused Screening - baoquankhu1.vn
Surprises Report: What are the future prospects of Elicio Therapeutics Inc2026 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Elicio Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 9HA | US28657F1030 - marketscreener.com
Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's What You Should Know - Yahoo Finance
Valuation Update: Can Elicio Therapeutics Inc benefit from deglobalization2026 Stock Rankings & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Launches New $100 Million ATM Program - The Globe and Mail
Elicio Therapeutics Reports Inducement Grants - Elicio Therapeutics
Biotech new hire lands 1,600 stock options at Elicio Therapeutics - Stock Titan
Rodman & Renshaw initiates coverage of Elicio Therapeutics (ELTX) with buy recommendation - MSN
[EFFECT] Elicio Therapeutics, Inc. SEC Filing - Stock Titan
Elicio Therapeutics launches new $100 million at-the-market stock offering - Investing.com India
Elicio Therapeutics, Inc. Enters At Market Issuance Sales Agreement for Up to $400 Million with Nasdaq Listing - Minichart
Elicio Therapeutics Launches $100M At-The-Mar... - Benzinga
Elicio Therapeutics Launches $100 Million ATM Program With B. Riley, JonesTrading and Ladenburg - TradingView
Elicio Therapeutics (NASDAQ: ELTX) launches $100M ATM, ends prior deal - Stock Titan
Elicio Therapeutics (NASDAQ: ELTX) launches $100M ATM sales program - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Elicio Therapeutics (ELTX), Silence Therapeutics (SLN) - The Globe and Mail
(ELTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
H.C. Wainwright raises Elicio Therapeutics price target to $17 By Investing.com - Investing.com Canada
H.C. Wainwright raises Elicio Therapeutics price target to $17 - Investing.com
Elicio Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
Elicio Therapeutics reports Q4 loss of $7.7 million - National Today
Elicio Therapeutics: Fourth Quarter Financial Overview - Bitget
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - Bitget
Elicio Therapeutics (NASDAQ: ELTX) highlights KRAS cancer vaccine and AMP platform - Stock Titan
Elicio Therapeutics 10-K: Net loss $(39.6)M, EPS $(2.58) — Y/E Dec 31, 2025 - TradingView
Elicio Therapeutics (NASDAQ: ELTX) files $400M shelf for stock, debt and warrants - Stock Titan
Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Elicio Therapeutics (Nasdaq: ELTX) narrows 2025 loss and advances ELI-002 toward Phase 3 - Stock Titan
CEO Change: Does Elicio Therapeutics Inc meet Warren Buffetts criteria2026 Big Picture & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Elicio Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Rodman & Renshaw initiates Elicio Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
Rodman & Renshaw initiates Elicio Therapeutics stock with buy rating - Investing.com Nigeria
Whats next for Elicio Therapeutics Inc stock2026 Price Action Summary & Short-Term High Return Ideas - baoquankhu1.vn
Aug Closing: Is Elicio Therapeutics Inc a turnaround storyDay Trade & Safe Investment Capital Preservation Plans - baoquankhu1.vn
ELTX Technical Analysis & Stock Price Forecast - Intellectia AI
How (ELTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Elicio Therapeutics (NASDAQ: ELTX) files S-3/A delaying effective date - Stock Titan
Elicio Therapeutics Files $400 Million Mixed Shelf - marketscreener.com
Elicio Therapeutics to issue up to $400 million in securities - marketscreener.com
Elicio Therapeutics To Issue Up To $400 Million In Securities - TradingView
Elicio Therapeutics (NASDAQ: ELTX) files $400M shelf to offer stock, debt - Stock Titan
Analyst Downgrade: Can Elicio Therapeutics Inc lead its sector in growthFed Meeting & High Accuracy Swing Trade Signals - baoquankhu1.vn
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Bitget
Cancer immunotherapy firm Elicio to speak at TD Cowen health conference March 4 - Stock Titan
Elicio Therapeutics Inc (ELTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):